Now showing items 21-40 of 40

    • Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells 

      Aass, Kristin Roseth; Mjelle, Robin; Kastnes, Martin Haugrud; Tryggestad, Synne Stokke; van den Brink, Luca M; Roseth, Ingrid Aass; Westhrin, Marita; Zahoor, Muhammad; Moen, Siv Helen; Nedal, Tonje Marie Vikene; Buene, Glenn; Misund, Kristine; Sponaas, Anne-Marit; Ma, Qianli; Sundan, Anders; Groen, Richard WJ; Slørdahl, Tobias Schmidt; Waage, Anders; Standal, Therese (Journal article; Peer reviewed, 2021)
      Interleukin-32 (IL-32) is a nonclassical cytokine expressed in cancers, inflammatory diseases, and infections. Its expression is regulated by two different oxygen sensing systems; HIF1α and cysteamine dioxygenase (ADO), ...
    • Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial 

      Sonja Zweegman, Zweegman; Claudia A M Stege, A; Haukås, Einar; Schjesvold, Fredrik H; Mark-David Levin, Levin; Waage, Anders; Rineke B L Leys, B; Saskia K Klein, K; Szatkowski, Damian Lukasz; Per Axelsson, Axelsson; Trung Hieu Do, Hieu; Dorota Knut-Bojanowska, Knut-Bojanowska; Ellen van der Spek, van; Asta Svirskaite, Svirskaite; Anja Klostergaard, Klostergaard; Morten Salomo, Salomo; Celine Blimark, Blimark; Paula F Ypma, F; Ulf-Henrik Mellqvist, Mellqvist; Pino J Poddighe, J; Marian Stevens-Kroef, Stevens-Kroef; Niels W C J van de Donk, W; Pieter Sonneveld, Sonneveld; Markus Hansson, Hansson; Bronno van der Holt, van; Niels Abildgaard, Abildgaard (Peer reviewed; Journal article, 2020)
    • Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma 

      Lund, Johan; Gruber, Astrid; Lauri, Birgitta; Duru, Adil Doganay; Blimark, Cecilie; Swedin, Agneta; Hansson, Markus; Forsberg, Karin; Ahlberg, Lucia; Carlsson, Conny; Waage, Anders; Gimsing, Peter; Vangsted, Annette Juul; Frølund, Ulf; Holmberg, Erik; Gahrton, Gösta C.A.; Alici, Evren; Hardling, Mats; Mellqvist, Ulf-Henrik; Nahi, Hareth (Journal article; Peer reviewed, 2018)
      Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once ...
    • Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia – Follow-up of the RITP study 

      Tjønnfjord, Eirik; Holme, Pål Andre; Darne, Bernadette; Khelif, Abderrahim; Waage, Anders; Michel, Marc; Romdhan, Neila Ben; Ghanima, Waleed Khalid (Peer reviewed; Journal article, 2020)
      RITP was a double‐blind randomized, 78‐week follow‐up trial in which 109 adults with immune thrombocytopenias (ITP) who failed to achieve adequate response to steroids, were randomized to receive rituximab or placebo. Here, ...
    • Marevan® som sekundær VTE-profylakse 

      Nesje, Øyvind Vestermo; Vik, Alexander Berge (Master thesis, 2013)
      Bakgrunn: 25-50% av venøse tromboembolismer (VTE) regnes som uprovoserte. Mange av disse pasientene er kandidater for livslang antikoagulasjonsbehandling. Nye retningslinjer for behandling av disse pasientene er i ferd med ...
    • Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report 

      Murray, David L.; Puig, Noemi; Kristinsson, Sigurður Y.; Usmani, Saad; Dispenzieri, Angela; Bianchi, Giada; Kumar, Shaji; Chng, Wee Joo; Hajek, Roman; Paiva, Bruno; Waage, Anders; Rajkumar, S. Vincent; Durie, Brian (Peer reviewed; Journal article, 2021)
      Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect ...
    • Monitoring multiple myeloma by quantification of recurrent mutations in serum 

      Rustad, Even Holth; Coward, Eivind; Skytøen, Emilie R; Misund, Kristine; Holien, Toril; Standal, Therese; Børset, Magne; Beisvag, Vidar; Myklebost, Ola; Meza, Leonardo Zepeda; Hong, Yan Dai; Sundan, Anders; Waage, Anders (Journal article; Peer reviewed, 2017)
      Circulating tumor DNA is a promising biomarker to monitor tumor load and genome alterations. We explored the presence of circulating tumor DNA in multiple myeloma patients and its relation to disease activity during long-term ...
    • Multiple Myeloma-study of cellular sensitivity to proteasome inhibitors 

      Baranowska, Katarzyna Anna (Doctoral theses at NTNU;2018:273, Doctoral thesis, 2018)
      Myelomatose (benmargskreft) – en studie av kreftcellenes følsomhet for kreftmedisiner i gruppen proteasomhemmere Myelomatose er en kreftform som utvikler seg i beinmargen og karakteriseres av ukontrollert vekst av de ...
    • MYC amplifications in myeloma cell lines; correlation with MYC-inhibitor efficacy 

      Holien, Toril; Misund, Kristine; Olsen, Oddrun Elise; Baranowska, Katarzyna Anna; Buene, Glenn; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2015)
      In multiple myeloma, elevated MYC expression is related to disease initiation and progression. We found that in myeloma cell lines, MYC gene amplifications were common and correlated with MYC mRNA and protein. In primary ...
    • Optimization and Validation of Digital Droplet PCR assays for Detection of circulating tumor DNA in serum/plasma from patients with Multiple Myeloma 

      Skytøen, Emilie Ranheim (Master thesis, 2017)
      Circulating tumor DNA (ctDNA) has been shown as a promising biomarker for monitoring several tumor types. We want to study the use of ctDNA in monitoring multiple myeloma, by use of digital droplet PCR (ddPCR). The objective ...
    • Patterns of previous and secondary malignancies in patients with multiple myeloma 

      Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2021)
      Objectives: In contrast to secondary primary malignancies (SPM) following multiple myeloma (MM), less is known about previous malignancies. We therefore conducted a population-based study to assess the patterns of previous ...
    • PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy 

      Sponaas, Anne-Marit; Nejati Moharrami, Neda; Feyzi, Emadoldin; Standal, Therese; Rustad, Even Holth; Waage, Anders; Sundan, Anders (Peer reviewed; Journal article, 2015)
      In this study we set out to investigate whether anti PDL1 or PD–1 treatment targeting the immune system could be used against multiple myeloma. DCs are important in regulating T cell responses against tumors. We therefore ...
    • Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia 

      Zatula, Alexey; Dikic, Aida; Mulder, Teska Celine; Sharma, Animesh; Vågbø, Cathrine Broberg; Sousa, Mirta; Waage, Anders; Slupphaug, Geir (Peer reviewed; Journal article, 2017)
      Plasma cell leukemia is a rare and aggressive plasma cell neoplasm that may either originate de novo (primary PCL) or by leukemic transformation of multiple myeloma (MM) to secondary PCL (sPCL). The prognosis of sPCL is ...
    • Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials 

      Palumbo, Antonio; Waage, Anders; Hulin, Cyrille; Beksac, M; Zweegman, Sonja; Gay, Francesca; Gimsing, Peter; Leleu, X; Wijermans, P; Sucak, G; Pezzatti, S; Juliusson, Gunnar; Pegourie, B; Schaafsma, Marije; Galli, M; Turesson, Ingemar; Kolb, B; van der Holt, B; Baldi, I; Rolke, Jürgen; Ciccone, G; Wetterwald, M; Lokhorst, H; Boccadoro, Mario; Rodon, P; Sonneveld, Pieter (Journal article; Peer reviewed, 2013)
      Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and is now considered a standard of care for patients not eligible for transplantation. However, this treatment is a ...
    • The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: Recommendations from the European Myeloma Network 

      van de Donk, Niels W.C.J.; Palumbo, Antonio; Johnsen, Hans Erik; Engelhardt, Monika; Gay, Francesca; Gregersen, Henrik; Hájek, Roman; Kleber, Martina; Ludwig, Heinz; Morgan, Gareth; Musto, Pellegrino; Plesner, Torben; Sezer, Orhan; Terpos, Evangelos; Waage, Anders; Zweegman, Sonja; Einsele, Hermann; Sonneveld, Pieter; Lokhorst, Henk (Journal article; Peer reviewed, 2014)
      Monoclonal gammopathy of undetermined significance is one of the most common pre-malignant disorders. IgG and IgA monoclonal gammopathy of undetermined significance are precursor conditions of multiple myeloma; light-chain ...
    • The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression 

      Ali, Mina; Ajore, Ram; Wihlborg, Anna-Karin; Niroula, Abhishek; Swaminathan, Bhairavi; Johnsson, Ellinor; Stephens, Owen W; Morgan, Gareth; Meissner, Tobias; Turesson, Ingemar; Goldschmidt, Hartmut; Mellqvist, Ulf-Henrik; Gullberg, Urban; Hansson, Markus; Hemminki, Kari; Nahi, Hareth; Waage, Anders; Weinhold, Niels; Nilsson, Björn (Journal article; Peer reviewed, 2018)
      Recently, we identified ELL2 as a susceptibility gene for multiple myeloma (MM). To understand its mechanism of action, we performed expression quantitative trait locus analysis in CD138+ plasma cells from 1630 MM patients ...
    • The proportion of CD16+CD14dim monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma 

      Sponaas, Anne-Marit; Moen, Siv Helen; Liabakk, Nina-Beate; Feyzi, Emadoldin; Holien, Toril; Kvam, Solveig; Grøseth, Lill Anny Gunnes; Størdal, Berit Fladvad; Buene, Glenn; Espevik, Terje; Waage, Anders; Standal, Therese; Sundan, Anders (Journal article; Peer reviewed, 2015)
      Multiple myeloma is an incurable cancer with expansion of malignant plasma cells in the bone marrow. Previous studies have shown that monocytes and macrophages in the bone marrow milieu are important for tumor growth ...
    • Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma 

      Swaminathan, Bhairavi; Thorleifsson, Gudmar; Jöud, Magnus; Ali, Mina; Johnsson, Ellinor; Ajore, Ram; Sulem, Patrick; Halvarsson, Britt-Marie; Eyjolfsson, Gudmundur I.; Haraldsdottir, Vilhelmina; Hultman, Christina; Ingelsson, Erik; Kristinsson, Sigurdur Y; Kähler, Anna Katarina; Lenhoff, Stig; Masson, Gisli; Mellqvist, Ulf-Henrik; Månsson, Robert; Nelander, Sven; Olafsson, Isleifur; Sigurdardóttir, Olöf Gudrun; Steingrimsdottir, Hlif; Vangsted, Annette; Vogel, Ulla; Waage, Anders; Nahi, Hareth; Gudbjartsson, Daniel F.; Rafnar, Thorunn; Turesson, Ingemar; Gullberg, Urban; Stefansson, Kari; Hansson, Markus; Thorsteinsdottir, Unnur; Nilsson, Björn (Journal article; Peer reviewed, 2015)
      Multiple myeloma (MM) is characterized by an uninhibited, clonal growth of plasma cells. While first-degree relatives of patients with MM show an increased risk of MM, the genetic basis of inherited MM susceptibility is ...
    • Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group 

      Hillengass, J; Moulopoulos, LA; Delorme, S; Koutoulidis, V; Mosebach, J; Hielscher, T; Drake, M.; Rajkumar, SV; Oestergaard, B; Abildgaard, N; Hinge, M; Plesner, T; Suehara, Y; Matsue, K; Withofs, N; Caers, J; Waage, Anders; Goldschmidt, H; Dimopoulos, MA; Lentzsch, S; Durie, B; Terpos, E (Journal article; Peer reviewed, 2017)
      For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) has been implemented into the diagnostic criteria ...
    • Why do myeloma patients have bone disease? A historical perspective. 

      Børset, Magne; Sundan, Anders; Waage, Anders; Standal, Therese (Peer reviewed; Journal article, 2019)
      The question of how myeloma cells cause destruction of skeletal tissue has interested scientists for many years, and knowledge in this field has developed in parallel with the understanding of physiological bone remodeling. ...